| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 02/16/2005 | EP1506972A1 Insulin-like growth factor (IGF) I mutant variants |
| 02/16/2005 | EP1506786A1 Medicinal compositions containing ghrelin |
| 02/16/2005 | EP1506285A2 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| 02/16/2005 | EP1506211A1 C-aryl glucoside sglt2 inhibitors and method |
| 02/16/2005 | EP1506205A2 Novel azacyclic ethynyl derivatives |
| 02/16/2005 | EP1506200A2 Novel diazabicyclic biaryl derivatives |
| 02/16/2005 | EP1506011A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 02/16/2005 | EP1506002A2 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies |
| 02/16/2005 | EP1505982A1 Trimegestone and estrogens for treating post menopausal disorders |
| 02/16/2005 | EP1505968A1 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
| 02/16/2005 | EP1421099B1 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
| 02/16/2005 | EP1397365B1 Heteroaryl-diazabicyclo-alkanes as cns-modulators |
| 02/16/2005 | EP1377584B1 Novel cyclohexenyl phenyl diazepines as vasopressin and oxytocin receptor modulators |
| 02/16/2005 | EP1281709B1 Novel heterocyclic compounds with anti-inflammatory activity |
| 02/16/2005 | EP1246814B1 Compounds and methods for modulation of estrogen receptors |
| 02/16/2005 | EP1246792A4 Compounds and compositions for delivering active agents |
| 02/16/2005 | EP1244617B1 Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone |
| 02/16/2005 | EP0634896B1 Evaluation of patients with progressive immunosuppression |
| 02/16/2005 | CN1582301A Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 02/16/2005 | CN1582275A Calcium antagonistic compound |
| 02/16/2005 | CN1582154A Method for treating or prophylaxis of aldo sterone-medicated phthogenic effects in subjwect using epoxy-steroidal aldosterone antagonist |
| 02/16/2005 | CN1582152A composition of estrogen and other hormons with ascorbate, lysine, proline and other substances |
| 02/16/2005 | CN1582147A Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 02/16/2005 | CN1189168C Use of (-)-(3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance type 2-diabetes, hyperlipidemia and hyperuricemia |
| 02/15/2005 | US6855528 Administering a covalently reactive antigen analog (CRAA) having an an epitope recognized irreversibly bound by catalytic antibody; autoimmune disease; a lymphoproliferative disorder; anticarcinogenic, -tumor, -inflammatory agents |
| 02/15/2005 | US6855512 Phenylacetic or heteroarylacetic acid derivatives; retinoid like activity |
| 02/15/2005 | CA2124339C Novel 19-nor steroids having a thiocarbon-containing chain in the 11 beta position, a method for preparing same and intermediates therefor, medicinal uses thereof and compositionscontaining said steroids |
| 02/10/2005 | WO2005012347A2 Novel insulin derivatives |
| 02/10/2005 | WO2005012346A1 Long lasting insulin derivatives and methods thereof |
| 02/10/2005 | WO2005012272A1 Benzoxazepine compound |
| 02/10/2005 | WO2005012269A1 Novel azole compound |
| 02/10/2005 | WO2005011727A1 Combination of an activator of soluble guanylate cyclase and an ace-inhibitor for the treatment of a cardiovascular or metabolic disorder |
| 02/10/2005 | WO2005011680A1 Use of angiotensin ii receptor antagonists, especially telmisartan, in order to increase insulin sensitivity |
| 02/10/2005 | WO2004110983A3 New benzamides as pparϒ modulators |
| 02/10/2005 | WO2004016647A3 Fragments of proinsulin c-peptide |
| 02/10/2005 | US20050033414 Drug-eluting stent with multi-layer coatings |
| 02/10/2005 | US20050033055 Edg receptor agonists |
| 02/10/2005 | US20050032890 Aniline-derived ligands for the thyroid receptor |
| 02/10/2005 | US20050032874 Indole derivatives |
| 02/10/2005 | US20050032854 Administering 2-ethoxy-1-[[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid or a salt as a hypotensive or an antidiabetic agent; impaired glucose tolerance |
| 02/10/2005 | US20050032851 E. g.,N-[[4-[2-(5-Methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]acetamide; side effect reduction; non-steroidal antiinflammatory agents; antiarthritic agents; analgesics; antipyretics; acylation of the corresponding sulfoamide by an anhydride a solvent and base |
| 02/10/2005 | US20050032820 Novel spiro compounds |
| 02/10/2005 | US20050032779 enzyme inhibitors such as 2-[4-(4-Dimethylaminophenyl)piperazin-1-yl]4,5-dihydroimidazo[4,5,1-ij]quinolin-6-one, used for treating or preventing disorders in which poly/ADP-ribose/ polymerase is involved |
| 02/10/2005 | US20050032761 Lipid profile modulation |
| 02/10/2005 | US20050032706 Hypoglycaemic peptides and methods of use thereof |
| 02/10/2005 | DE19906152B4 Wirkstoffhaltige Laminate für Transdermalsysteme Active substance laminates for transdermal |
| 02/10/2005 | CA2534464A1 Benzoxazepine compound |
| 02/10/2005 | CA2531988A1 Novel insulin derivatives |
| 02/09/2005 | EP1505074A1 Histamine receptor h3 ordinary activity mutant and utilization thereof |
| 02/09/2005 | EP1505072A2 Eplerenone crystalline form exhiniting enhanced dissolution rate |
| 02/09/2005 | EP1504124A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions |
| 02/09/2005 | EP1503779A2 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 02/09/2005 | EP1503751A1 Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures |
| 02/09/2005 | EP1401446B1 Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen |
| 02/09/2005 | EP1242121B1 Polypeptide compositions with improved stability |
| 02/09/2005 | EP1200076A4 Calcilytic compounds |
| 02/09/2005 | EP1105376B1 Oxindole derivatives as growth hormone releasers |
| 02/09/2005 | EP0700438B1 Opioid receptors: compositions and methods |
| 02/09/2005 | CN1578781A 1, 8 naphthyridine derivatives and their use to treat diabetes and related disorders |
| 02/09/2005 | CN1578780A 1, 6-naphthyridine derivatives as antidiabetics and pharmaceutical compositions containing them |
| 02/09/2005 | CN1576275A Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 02/09/2005 | CN1575816A Compounds for the treatment of female sexual dysfunction |
| 02/09/2005 | CN1188405C New Morpholinobenzamide salts |
| 02/09/2005 | CN1188403C Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/09/2005 | CN1188111C Dry powder compositions having improved dispersivity |
| 02/08/2005 | US6852749 Pyrazolidinol compounds |
| 02/08/2005 | US6852738 Potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compoundsare for treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, |
| 02/08/2005 | US6852727 Inhibitors of Janus protein tyrosine kinases (Jak), and as such are useful as immunosuppressants, and in the treatment of diseases including asthma, allergies, autoimmune diseases. |
| 02/08/2005 | US6852725 Imidazolyl derivatives |
| 02/08/2005 | US6852720 Thiazol-2-yl-imine compounds as PDE-7 inhibitors |
| 02/08/2005 | US6852701 Sulfamate compound |
| 02/08/2005 | US6852518 Glycosyl sulfotransferases GST-4α, GST-4β, and GST-6 |
| 02/03/2005 | WO2005010189A1 OLIGONUCLEOTIDE INHIBITING THE EXPRESSION OF StAR-BINDING PROTEIN (SBP) GENE AND METHOD THEREFOR |
| 02/03/2005 | WO2005009949A2 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
| 02/03/2005 | WO2005009480A2 Implants containing codrugs |
| 02/03/2005 | WO2005009433A1 Use of 3,5 diiodothyronine as regulators of lipid metabolism |
| 02/03/2005 | WO2003101461A8 Norethindrone sustained release formulations and methods associated therewith |
| 02/03/2005 | US20050027114 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 02/03/2005 | US20050027015 Feed containing cysteamine or a salt thereof and a stabilizer such as cyclodextrin; increased milk production in cows |
| 02/03/2005 | US20050026985 Such as N-{5-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]pentanoyl}tyrosinamide; useful for the treatment of mammalian infertility |
| 02/03/2005 | US20050026956 Carbinols for the treatment of neuropathic dysfunction |
| 02/03/2005 | US20050026942 Chemokine receptor binding heterocyclic compounds |
| 02/03/2005 | US20050026905 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| 02/03/2005 | US20050026889 Treating acne, seborrhea, hirsutism, alopecia, mastodynia, prostate hyperplasia and carcinoma, virilization syndromes in the female, early puberty, use in inhibition of sexual aggressiveness in the male, male contraception |
| 02/03/2005 | US20050026888 Formulation containing anti-inflammatory androstane derivatives |
| 02/03/2005 | US20050026839 Conformationally constrained parathyroid hormone (pth) analogs |
| 02/03/2005 | US20050026822 Human 3 relaxin |
| 02/03/2005 | US20050026233 Using bioassay for loss-of-function mutations in protein kinase (LKB1) as diagnostic tool in detection of cell proliferative disorders; AMP-activated protein kinase (AMPK) and treatment of diabetic, cardiovascular and dietetic disorders |
| 02/03/2005 | US20050025827 Pharmaceutical formulation for contraception and hormone-replacement therapy |
| 02/03/2005 | US20050025806 A silicone support of methylvinylsiloxane polymer including a fumed silca reinforcement filler; growth and/or reproduction-associated drug, derivative or analogue and carrier; each implant of insufficient size and/or payload for the predetermined threshold blood level of indicated drug; high-speed |
| 02/03/2005 | US20050025751 Increased or reduced expression of tumor necrosis factors or interleukins; antiinflammatory agents; autoimmune diseases |
| 02/03/2005 | CA2530047A1 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
| 02/02/2005 | EP1501859A1 17a-FLUOROALKYL-11BETA-BENZALDOXIME-STEROIDS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING SAID STEROIDS AND THE USE THEREOF IN THE PRODUCTION OF MEDICAMENTS |
| 02/02/2005 | EP1501858A2 Further syntheses of cyproterone acetate |
| 02/02/2005 | EP1501835A2 2-(quinolonyl)-fused heterocycles as androgen receptor modulators |
| 02/02/2005 | EP1501819A1 Estrogen receptor modulators |
| 02/02/2005 | EP1501539A1 Method for control of depression using c terminal growth hormone (gh) fragment |
| 02/02/2005 | EP1501512A2 4-azasteroid derivatives as androgen receptor modulators |
| 02/02/2005 | EP1379257A4 Prodrugs of anticancer agents employing substituted aromatic acids |
| 02/02/2005 | EP1292591B1 Substituted bicyclic derivatives for the treatment of abnormal cell growth |